Stephen C. Knight, M.D. (President, Fidelity Biosciences)
Chairman
Dr. Knight has worked in the pharmaceutical and biotechnology industries for over sixteen years. Prior to joining Fidelity in 2003, Dr. Knight was president and chief operating officer for EPIX Pharmaceuticals in Cambridge, Massachusetts. For six years before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., primarily as a senior consultant in Cambridge and Brussels, Belgium specializing in mergers and acquisitions in the pharmaceutical industry. Prior to 1990, Dr. Knight performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institutes of Health, and at Yale University. Dr. Knight holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Yale School of Organization and Management. Dr. Knight received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa. Dr. Knight currently serves as chairman of the Board of Directors for Veritas Medicine and EnVivo Pharmaceuticals. He also serves on the Board of Directors of Microbia, U.S. Genomics, and FoldRx Pharmaceuticals.
Randall Carpenter, M.D. (CEO, Seaside Therapeutics)
Dr. Carpenter is Founder, President and CEO of Seaside Therapeutics, a drug discovery company focused on developing novel therapeutics for disorders of brain development such as Fragile X and autism.Dr. Carpenter has over 25 years experience in medicine, basic science and clinical research, pharmaceutical drug development and management. He has held a number of leadership positions in the pharmaceutical and biotechnology industries including: President and CEO of Sention, Vice-President of Clinical Research & Development and Regulatory Affairs at Adolor Corporation, Director of Clinical Research at Astra USA, and Member of the Global Therapeutic Area Team at Astra Pain Control Sweden.Dr. Carpenter has broad experience leading pharmaceutical research and development teams submitting a number of successful IND’s, NDA’s and sNDA’s.Prior to industry, Dr. Carpenter held academic faculty appointments at the University of Washington and Wake Forest University. Dr. Carpenter has co-authored 65 journal articles and seven patents and has served as editor-in-chief or on the editorial boards of four medical journals.He has frequently been an invited speaker at national and international meetings and symposia and has been an invited visiting professor to numerous domestic and international universities and medical schools.Dr. Carpenter is Board Certified in Anesthesiology and Pain Management, completed a fellowship in pharmacokinetics at the University of California San Francisco and a sabbatical in molecular biology at the University of Washington.
C. Thomas Caskey, M.D. (Brown Foundation Institute of Molecular Medicine - Univ. of Texas)
C. Thomas Caskey, M.D., F.A.C.P., is Director and Chief Executive Officer-Elect and Chief Operating Officer of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), at the University of Texas Health Science Center at Houston. Dr. Caskey was founding director of Houston-based Cogene Biotech Ventures and Cogene Ventures, venture capital funds supporting early-stage biotechnology and life sciences companies. The fund, founded in March 2000, invested in companies that utilize genome technology to enable drug discovery in high growth therapeutic specialties such as cancer, neurology and the metabolic diseases of obesity and diabetes. Dr. Caskey has received numerous academic and industry-related honors. He is a member of the National Academy of Sciences and the Institute of Medicine. He has served as president of American Society of Human Genetics, the Human Genome Organization and The Academy of Medicine, Engineering and Science of Texas (TAMEST). He previously served as senior vice president for human genetics and vaccines discovery at Merck Research Laboratories from 1994 to 2000 and as president of the Merck Genome Research Institute from 1998 to 2000. He received the Distinguished Texas Geneticist Award from the Texas Genetics Society in 1998 and serves on Texas Governor Rick Perry’s Council on Science and Biotechnology, which makes funding recommendations for the $200 million Texas Emerging Technology Fund. Dr. Caskey earned his medical degree from Duke University School of Medicine and his undergraduate degree from the University of South Carolina. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases and Molecular Diagnostics.
Mark A. Peterson (Retired Executive, Fidelity Investments)
Before retiring recently Mark A. Peterson served as an executive for Fidelity Investments, America’s largest mutual-fund company. In his many roles at the company, Peterson held executive positions advising Fidelity in legal matters and information-technology issues, and directing the company’s venture investing in biotechnology interests. Peterson earned his bachelor’s degree from Pennsylvania State University and his juris doctorate from Temple University School of Law.
John Remondi (Fidelity Investments)
Mr. Remondi has served as President of Fidelity Investors Management LLC (FIML) since January 2001. Prior to this role, Mr. Remondi was Vice President of FMR Corp. and Managing Director of Fidelity Ventures. Mr. Remondi joined Fidelity in 1983 as Chief Financial Officer for FMR Corp. and served in the position until joining Fidelity Ventures in 1991. Mr. Remondi is a graduate of Boston College and Boston University School of Management.
Robert Weisskoff, Ph.D. (Partner, Fidelity Biosciences)
Dr. Weisskoff has worked extensively in both academia and the bioscience industry for the past twenty years. Prior to joining Fidelity in 2004, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, and on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 5 US patents. Dr. Weisskoff holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa. Dr. Weisskoff currently serves on the Board of Directors for Acorn, Bioconnect, Intranasal Therapeutics, Inc., Tetraphase, Topaz, Transave, ViewRay, and EnVivo Pharmaceuticals.
